Sign in Subscribe
Biotechnology industries

Cephalon, Inc. Reports 42% Increase in 2004 Revenue

Strategic Insights

— 1 min read

Cephalon, Inc. (CEPH) has reported a significant increase in revenue for 2004, with sales reaching $980.4 million, a 43% increase from 2003. The company's three lead products have posted outstanding sales increases, positioning Cephalon for significant growth ahead. The company's chairman and CEO, Frank Baldino Jr., PhD, highlighted the company's achievements in 2004, citing the success of four new products that are expected to deliver significant sales and earnings growth for the company in the years ahead.

Key Takeaways:

  • Cephalon, Inc. (CEPH) reported 2004 revenue of $1.0 billion, a 42% increase over 2003.
  • The company recorded charges related to the acquisition of Cima Labs, Inc., and the exchange or repurchase of Cephalon notes, resulting in a diluted loss per share for 2004 of $1.31.
  • Excluding these items and amortization expense, diluted adjusted earnings per share were $2.42, a 31% increase over the comparable figure of $1.85 recorded in 2003.
  • All three lead products posted outstanding sales increases, with sales of $980.4 million in 2004, compared with 2003 sales of $685.3 million, a 43% increase.
  • The company expects to file four new drug applications (NDAs) in 14 months, with the success of these products expected to drive significant sales and earnings growth.
  • Frank Baldino Jr., PhD, chairman and CEO, highlighted the company's achievements in 2004, citing the quadrupling of sales since 2001.

Statistics:

  • 2004 revenue: $1.0 billion, a 42% increase from 2003.
  • Diluted loss per share for 2004: $1.31.
  • Diluted adjusted earnings per share for 2004: $2.42, a 31% increase over 2003.
  • 2003 revenue: $685.3 million.
  • 2004 revenue: $980.4 million, a 43% increase from 2003.
  • Sales of lead products: all three products posted outstanding sales increases.
  • Four new products expected to be approved: ATTENACE, Nuvigil, OraVescent Fentanyl, and GABITRIL for generalized anxiety disorder.

Sources:

  • Cephalon, Inc. press release
  • NewsRx.com
  • Health & Medicine Week via NewsRx.com.

Read more